Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer.

MLA

Ragusa, Francesca, et al. “Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer.” International Journal of Molecular Sciences, vol. 23, no. 10, May 2022. EBSCOhost, https://doi.org/10.3390/ijms23105731.

APA

Ragusa, F., Ferrari, S. M., Elia, G., Paparo, S. R., Balestri, E., Botrini, C., Patrizio, A., Mazzi, V., Guglielmi, G., Foddis, R., Spinelli, C., Ulisse, S., Antonelli, A., & Fallahi, P. (2022). Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. International Journal of Molecular Sciences, 23(10). https://doi.org/10.3390/ijms23105731

Chicago

Ragusa, Francesca, Silvia Martina Ferrari, Giusy Elia, Sabrina Rosaria Paparo, Eugenia Balestri, Chiara Botrini, Armando Patrizio, et al. 2022. “Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer.” International Journal of Molecular Sciences 23 (10). doi:10.3390/ijms23105731.